Media

Stockhead‘s Tim Boreham has reported on Racura Oncology announcing the site activation of Queen Mary Hospital in Hong Kong, enabling the commencement of patient recruitment for Phase 1 clinical trial of RC220 in combination with doxorubicin in advanced solid tumour patients. The company hopes that as well as attacking the tumours, RC220 will protect the…

Samso’s Noel Ong has compiled the key highlights of Racura Oncology in this note, and outlined the upcoming inflection points for the company. In his analysis, Mr Ong writes: “Most of us have known someone who is in the predicament of being a patient of some form of cancer, so the path to finding a…

Racura Oncology has announced the results of the Phase 2 clinical trial of RC110 bisantrene for relapsed or refractory acute myeloid leukaemia (AML) has been published in the peer-reviewed British Journal of Haematology, as reported by Biotech Dispatch. Read the full article here.

Racura Oncology chief executive officer Dr Daniel Tillett talked with Proactive about the company’s key milestones this quarter, including the treatment of the first patient with its lead asset, RC220, a reformulated version of bisantrene. Watch the full interview here.

In this exclusive interview with The Capital Compass, Dr. Pete Smith from Racura Oncology discusses the company’s groundbreaking work on RC220, a reformulated cancer drug with a proven history of efficacy and safety. Watch the full interview here.

Racura Oncology Ltd (ASX:RAC, OTC:RAONF) has successfully dosed the first patient with the combination of its lead drug RC220 and doxorubicin in its Phase 1 clinical trial targeting advanced solid tumours.  Read the full article here.

The Australian reports Racura Oncology has achieved a major milestone, as the company has safely and successfully dosed its first patients for its Phase 1 clinical trial in advanced solid tumours. Read the full report here.

Racura CEO and Managing Director Dr Daniel Tillett speaks with ausbiz about the company’s recent major milestone – the first patient has been safely and successfully dosed for the RC220 Phase 1 clinical trial in advanced solid tumours. Watch the full interview via this link.

Racura Oncology CEO and MD Daniel Tillett speaks with Proactive about the activation of the first Australian clinical site for the RC220 Phase I solid tumour trial. Dr Tillett confirms that the trial is now underway and open to patient enrolment. Watch the full interview below. Additional report can be found here.